Long COVID affects hundreds of millions worldwide, yet no FDA-approved treatments exist despite its serious social and economic impacts. In 2025, research reached a turning point: several early clinical trials failed to show benefits, while more advanced, better-designed trials began enrolling patients. A series of feature articles highlighted this shift, exploring promising treatment approaches and the next generation of studies aimed at improving outcomes.
